The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > REGULATORY
REGULATORY
- “Kobe Model” Offers Unique Subsidy to Diagnose Dementia, Test Eligibility for Lecanemab
September 18, 2024
- 9 LDP Leader Candidates Showcase Pharma Agendas in Campaign
September 17, 2024
- FY2025 Budget Request Would Add 7 PMDA Reviewers for Startup Consultations
September 13, 2024
- Japan Approves Meiji’s JN.1-Directed COVID-19 Vaccine
September 13, 2024
- MHLW Lays Out Updated Discussion Timeline for PMD Act Amendment
September 13, 2024
- Trodelvy Nears Japan Approval as It Sails through Panel Review
September 13, 2024
- Kamikawa Runs for LDP Presidency, Resolved to Empower Healthcare Realm
September 12, 2024
- Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
September 12, 2024
- Antivirals Push Up Japan’s Drug Spending in FY2023: MHLW
September 12, 2024
- Ex-Minister Kato Joins Fray in LDP Race, Pledges Inflation-Linked Drug Prices
September 11, 2024
- MHLW Proposes Periodic Survey of Vaccine Prices in Japan
September 11, 2024
- Takaichi Vows to Bolster Japan’s Self-Sufficiency of Drugs, Vaccines in LDP Race
September 11, 2024
- Japan Extends Re-Examination Period for Entyvio, Zintus
September 11, 2024
- AMED Research Exploring Low-Cost Method to Analyze Nitrosamine Impurities
September 11, 2024
- First Drug Delisting in Simplified Process Slated for March-End 2026: MHLW
September 10, 2024
- Eisai COO Calls for LDP Collaboration in AD Diagnosis, Treatment
September 10, 2024
- MHLW to Accept English Dossiers from Foreign Makers
September 9, 2024
- MHLW Proposes Scope of Observational Research Subject to Clinical Trials Act
September 9, 2024
- MHLW Floats 3 Perspectives to Codify Rules for Drug Supply Management
September 9, 2024
- PMDA-Led Inspections Will Help Straighten Up Generic Makers: MHLW Councilor
September 6, 2024
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…